Secondary prevention of stroke

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 9, 2009, Pages 1103-1115

  MacDougall, Niall J J ^a   Amarasinghe, Sanjay ^b   Muir, Keith W ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

Cerebrovascular disease; Intracerebral hemorrhage; Secondary prevention; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; EPROSARTAN; GLICLAZIDE; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; IRBESARTAN; NITRENDIPINE; PERINDOPRIL; PIOGLITAZONE; PLACEBO; SIMVASTATIN; TELMISARTAN; WARFARIN;

ANGIOPLASTY; BLEEDING; BRAIN HEMORRHAGE; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; ELECTROCARDIOGRAM; GLYCEMIC CONTROL; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INCIDENCE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; RECURRENT DISEASE; REVIEW; RISK FACTOR; SECONDARY PREVENTION; STENT; STROKE; TRANSIENT ISCHEMIC ATTACK; VITAMIN SUPPLEMENTATION;

CLINICAL TRIALS AS TOPIC; HUMANS; ISCHEMIC ATTACK, TRANSIENT; RECURRENCE; RISK FACTORS; SECONDARY PREVENTION; STROKE;

EID: 70450209065     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.77     Document Type: Review

References (138)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global regional burden of disease risk factors, 2001: systematic analysis of population health data. Lancet 367(9524), 1747-1757 (2006).
2. Rothwell PM. The high cost of not funding stroke research: a comparison with heart disease and cancer. Lancet 357(9268), 1612-1616 (2001).
3. Adams HP Jr, del Zoppo G, Alberts MJ et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology Intervention Council, the Atherosclerotic Peripheral Vascular Disease Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 38(5), 1655-1711 (2007).
4. European Stroke Organization (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke transient ischaemic attack 2008. Cerebrovasc. Dis. 25(5), 457-507 (2008).
5. Scottish Intercollegiate Guidelines Network. Management of patients with stroke or TIA: assessment, investigation, immediate management secondary prevention. SIGN 108, 1-108 (2008).
6. Bamford J, Sercock P, Dennis M, Burn J, Warlow C. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project-1981-1986. 2. Incidence, case fatality rates overall outcome at one year of cerebral infarction, primary intracerebral subarachnoid hemorrhage. J. Neurol. Neurosurg. Psychiatr. 53(1), 16-22 (1990). (Pubitemid 20034358)
7. Rothwell PM, Coull AJ, Silver LE et al. Population-based study of event-rate, incidence, case fatality, mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 366(9499), 1773-1783 (2005).
8. Kidwell CS, Warach S. Acute ischemic cerebrovascular syndrome: diagnostic criteria. Stroke 34(12), 2995-2998 (2003). (Pubitemid 37517783)
9. Albers GW, Caplan LR, Easton JD et al. Transient ischemic attack - proposal for a new definition. NEJM 347(21), 1713-1716 (2002).
10. Saver JL. Proposal for a universal definition of cerebral infarction. Stroke 39(11), 3110-3115 (2008).
11. Cholesterol, diastolic blood pressure, stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet 346(8991-8992), 1647-1653 (1995).
12. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360(9349), 1903-1913 (2002).
13. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335(8692), 765-774 (1990). (Pubitemid 20106689)
14. Kidwell CS, Alger JR, Di Salle F et al. Diffusion MRI in patients with transient ischemic attacks. Stroke 30(6), 1174-1180 (1999). (Pubitemid 29259169)
15. Kidwell CS, Chalela JA, Saver JL et al. Comparison of MRI CT for detection of acute intracerebral hemorrhage. JAMA 292(15), 1823-1830 (2004).
16. Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJ. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups timing of surgery. Lancet 363(9413), 915-924 (2004). (Pubitemid 38388324)
17. Douen AG, Pageau N, Medic S. Serial electrocardiographic assessments significantly improve detection of atrial fibrillation 2.6-fold in patients with acute stroke. Stroke 39(2), 480-482 (2008). (Pubitemid 351619476)
18. Lerakis S, Nicholson WJ. Part I: use of echocardiography in the evaluation of patients with suspected cardioembolic stroke. Am. J. Med. Sci. 329(6), 310-316 (2005). (Pubitemid 40847699)
19. Dewar RI, Lip GY. Identification, diagnosis assessment of atrial fibrillation. Heart 93(1), 25-28 (2007).
20. Amarenco P, Cohen A, Tzourio C et al. Atherosclerotic disease of the aortic arch the risk of ischemic stroke. NEJM 331(22), 1474-1479 (1994). (Pubitemid 24356305)
21. Serena J, Marti-Fabregas J, Santamarina E et al. Recurrent stroke massive right-to-left shunt. Results from the prospective spanish multicenter (CODICIA) study. Stroke 39(12), 3131-3136 (2008).
22. The National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. NEJM 333(24), 1581-1587 (1995).
23. Lovett JK, Dennis MS, Sercock PA, Bamford J, Warlow CP, Rothwell PM. Very early risk of stroke after a first transient ischemic attack. Stroke 34(8), E138-E140 (2003).
24. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 284(22), 2901-2906 (2000).
25. Hill MD, Yiannakoulias N, Jeerakathil T, Tu JV, Svenson LW, Schopflocher DP. The high risk of stroke immediately after transient ischemic attack: a population-based study. Neurology 62(11), 2015-2020 (2004). (Pubitemid 38738214)
26. Coull AJ, Lovett JK, Rothwell PM. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education organisation of services. BMJ 328(7435), 326 (2004).
27. Coutts SB, Simon JE, Eliasziw M et al. Triaging transient ischemic attack minor stroke patients using acute magnetic resonance imaging. Ann. Neurol. 57(6), 848-854 (2005). (Pubitemid 40798623)
28. Rajajee V, Kidwell C, Starkman S et al. Early MRI outcomes of untreated patients with mild or improving ischemic stroke. Neurology 67(6), 980-984 (2006). (Pubitemid 44454588)
29. Johnston SC, Leira EC, Hansen MD, Adams HP Jr. Early recovery after cerebral ischemia risk of subsequent neurological deterioration. Ann. Neurol. 54(4), 439-444 (2003).
30. Johnston SC, Easton JD. Are patients with acutely recovered cerebral ischemia more unstable? Stroke 34(10), 2446-2450 (2003).
31. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes : a population-based study of functional outcome, survival, recurrence. Stroke 31(5), 1062-1068 (2000).
32. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, stroke in high risk patients. BMJ 324(7329), 71-86 (2002).
33. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143(1-2), 1-13 (1996). (Pubitemid 26402780)
34. Sercock PA, Counsell C, Gubitz GJ, Tseng MC. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst. Rev. 16(3), CD000029 (2008).
35. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348(9038), 1329-1339 (1996).
36. Sudlow C. Preventing further vascular events after a stroke or transient ischaemic attack: an update on medical management. Pract. Neurol. 8(3), 141-157 (2008). (Pubitemid 351850373)
37. De Schryver EL, Algra A, van Gijn J. Dipyridamole for preventing stroke other vascular events in patients with vascular disease. An update. Stroke 39, 1397-11139 (2008).
38. De Schryver EL, Algra A, van Gijn J. Dipyridamole for preventing stroke other vascular events in patients with vascular disease. Cochrane Database Syst. Rev. (3), CD001820 (2007). (Pubitemid 351816830)
39. Picano E. Dipyridamole in chronic stable angina pectoris; a randomized, double blind, placebo-controlled, parallel group study. Eur. Heart J. 22(19), 1785-1793 (2001). (Pubitemid 32929113)
40. Chang YJ, Ryu SJ, Lee TH. Dose titration to reduce dipyridamole-related headache. Cerebrovasc. Dis. 22(4), 258-262 (2006).
41. Costa J, Ferro JM, Matias-Guiu J, Alvarez-Sabin J, Torres F. Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst. Rev. (3), CD004296 (2005).
42. Lee JH, Park SY, Shin HK, Kim CD, Lee WS, Hong KW. Protective effects of cilostazol against transient focal cerebral ischemia chronic cerebral hypoperfusion injury. CNS Neurosci. Ther. 14(2), 143-152 (2008).
43. Diener HC, Bogousslavsky J, Brass LM et al. Aspirin clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet 364(9431), 331-337 (2004).
44. Bhatt DL, Fox KA, Hacke W et al. Clopidogrel aspirin versus aspirin alone for the prevention of atherothrombotic events. NEJM 354(16), 1706-1717 (2006).
45. Markus HS, Droste DW, Kaps M et al. Dual antiplatelet therapy with clopidogrel aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the clopidogrel aspirin for reduction of emboli in symptomatic carotid stenosis (CARESS) trial. Circulation, 111(17), 2233-2240 (2005). (Pubitemid 40632440)
46. Dittrich R, Ritter MA, Kaps M et al. The use of embolic signal detection in multicenter trials to evaluate antiplatelet efficacy: signal analysis quality control mechanisms in the CARESS (clopidogrel aspirin for reduction of emboli in symptomatic carotid stenosis) trial. Stroke 37(4), 1065-1069 (2006).
47. Kennedy J, Eliasziw M, Hill MD, Buchan AM. The fast assessment of stroke transient ischemic attack to prevent early recurrence (FASTER) trial. Seminars in Cerebrovascular Diseases Stroke 3(1), 25-30 (2003).
48. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM. Fast assessment of stroke transient ischaemic attack to prevent early recurrence (FASTER): a randomized controlled pilot trial. Lancet Neurol. 6(11), 961-969 (2007). (Pubitemid 47562312)
49. Connolly SJ, Pogue J, Hart RG et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. NEJM 360(20), 2066-2078 (2009).
50. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial. Lancet 367(9523), 1665-1673 (2006).
51. Sacco RL, Diener HC, Yusuf S et al. Aspirin extended-release dipyridamole versus clopidogrel for recurrent stroke. NEJM 359(12), 1238-1251 (2008).
52. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. NEJM 320(14), 904-910 (1989). (Pubitemid 19101595)
53. Atkins D, Psaty BM, Koepsell TD, Longstreth WT Jr, Larson EB. Cholesterol reduction the risk for stroke in men. A meta-analysis of randomized, controlled trials. Ann. Intern. Med. 119(2), 136-145 (1993). (Pubitemid 23286480)
54. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention carotid atherosclerosis: systematic review up-to-date meta-analysis. Stroke 35(12), 2902-2909 (2004). (Pubitemid 39565192)
55. Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br. J. Clin. Pharmacol. 57(5), 640-651 (2004).
56. Coull BM. Statin therapy after acute ischemic stroke in the heart protection study: is the role in recurrent stroke prevention now defined? Stroke 35(9), 2233-2234 (2004).
57. Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363(9411), 757-767 (2004).
58. Amarenco P, Bogousslavsky J, Callahan A 3rd et al. High-dose atorvastatin after stroke or transient ischemic attack. NEJM 355(6), 549-559 (2006).
59. Goldstein LB, Amarenco P, Szarek M et al. Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. Neurology 70(24 Pt 2), 2364-2370 (2008).
60. Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB. Statin treatment the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke 39(2), 497-502 (2008). (Pubitemid 351619482)
61. Sillesen H, Amarenco P, Hennerici MG et al. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis. A secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. Stroke 39(12), 3297-3302 (2008).
62. Blanco M, Nombela F, Castellanos M et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 69(9), 904-910 (2007). (Pubitemid 47329591)
63. Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure stroke: an overview of published reviews. Stroke 35(4), 1024 (2004).
64. Willmot M, Leonardi-Bee J, Bath PM. High blood pressure in acute stroke subsequent outcome: a systematic review. Hypertension 43(1), 18-24 (2004). (Pubitemid 38031905)
65. Leonardi-Bee J, Bath PM, Phillips SJ, Sercock PA. Blood pressure clinical outcomes in the international stroke trial. Stroke 33(5), 1315-1320 (2002). (Pubitemid 34517053)
66. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction secondary prevention of stroke other vascular events: a systematic review. Stroke 34(11), 2741-2748 (2003). (Pubitemid 37392777)
67. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. NEJM 342(3), 145-153 (2000).
68. Bosch J, Yusuf S, Pogue J et al. Use of ramipril in preventing stroke: double blind randomized trial. BMJ 324(7339), 699-702 (2002). (Pubitemid 34259143)
69. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358(9287), 1033-1041 (2001).
70. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin. Med. J. 108(9), 710-717 (1995).
71. Schrader J, Luders S, Kulschewski A et al. Morbidity mortality after stroke eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36(6), 1218-1226 (2005). (Pubitemid 40798742)
72. Williams B, Poulter NR, Brown MJ et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J. Hum. Hypertens. 18(3), 139-185 (2004). (Pubitemid 38425770)
73. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke of coronary heart disease. Br. Med. Bull. 50(2), 272-298 (1994). (Pubitemid 24165020)
74. Rodgers A, MacMahon S, Gamble G, Slattery J, Sercock P, Warlow C; the United Kingdom Transient Ischaemic Attack Collaborative Group. Blood pressure risk of stroke in patients with cerebrovascular disease. BMJ 313(7050), 147 (1996).
75. Bath P. High blood pressure as risk factor prognostic predictor in acute ischaemic stroke: when how to treat it? Cerebrovasc Dis, 17 Suppl 1, 51-57 (2004). (Pubitemid 38032521)
76. Geeganage C, Bath PM. Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database Syst. Rev. (4), CD000039 (2008).
77. Ahmed N, Wahlgren G. High initial blood pressure after acute stroke is associated with poor functional outcome. J Intern Med, 249(5), 467-473 (2001). (Pubitemid 34208951)
78. Rothwell PM, Howard SC, Spence JD. Relationship between blood pressure stroke risk in patients with symptomatic carotid occlusive disease. Stroke 34(11), 2583-2590 (2003).
79. Yusuf S, Diener HC, Sacco RL et al. Telmisartan to prevent recurrent stroke cardiovascular events. NEJM 359(12), 1225-1237 (2008).
80. Potter J, Robinson T, Ford G et al. CHHIPS (Controlling Hypertension Hypotension Immediately Post-Stroke) pilot trial: rationale design. J. Hypertens. 23(3), 649-655 (2005). (Pubitemid 40684725)
81. Rosendorff C. New insights into hypertension management in acute stroke: let the CHHIPS fall where they may. J. Clin. Hypertens. (Greenwich) 10(6), 425-426 (2008).
82. Schrader J, Luders S, Kulschewski A et al. The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 34(7), 1699-1703 (2003). (Pubitemid 36842630)
83. Anderson CS, Huang Y, Wang JG et al. Intensive blood pressure reduction in acute cerebral hemorrhage trial (INTERACT): a randomized pilot trial. Lancet Neurol. 7(5), 391-399 (2008).
84. COSSACS Trial Group. COSSACS (Continue or stop post-stroke antihypertensives collaborative study): rationale design. J. Hypertens. 23(2), 455-458 (2005).
85. Algra A, de Schryver EL, van Gijn J, Kappelle LJ, Koudstaal PJ. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst. Rev. (4), CD001342 (2001).
86. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischemia of arterial origin (ESPRIT): a randomized controlled trial. Lancet Neurol. 6(2), 115-124 (2007). (Pubitemid 46097527)
87. Mohr JP, Thompson JL, Lazar RM et al. A comparison of warfarin aspirin for the prevention of recurrent ischemic stroke. NEJM 345(20), 1444-1451 (2001).
88. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann. Neurol. 42(6), 857-865 (1997).
89. Chimowitz MI, Lynn MJ, Howlett-Smith H et al. Comparison of warfarin aspirin for symptomatic intracranial arterial stenosis. NEJM 352(13), 1305-1316 (2005). (Pubitemid 40411497)
90. Cervical Artery Dissection in Stroke Study Trial Investigators. Antiplatelet therapy vs. anticoagulation in cervical artery dissection: rationale design of the cervical artery dissection in stroke study (CADISS). Int. J. Stroke 2(4), 292-296 (2007).
91. Engelter ST, Brandt T, Debette S et al. Antiplatelets versus anticoagulation in cervical artery dissection. Stroke 38(9), 2605-2611 (2007). (Pubitemid 47329646)
92. European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342(8882), 1255-1262 (1993).
93. van Walraven C, Hart RG, Singer DE et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 288(19), 2441-2448 (2002).
94. Saxena R, Koudstaal P. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation a history of stroke or transient ischemic attack. Cochrane Database Syst. Rev. 18(4), CD000187 (2004).
95. van Walraven C, Hart RG, Connolly S et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation. The atrial fibrillation investigators. Stroke 40(4), 1410-1416 (2009).
96. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146(12), 857-867 (2007).
97. Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS. A randomized controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 36(2), 151-156 (2007). (Pubitemid 46455393)
98. Mant J, Hobbs FD, Fletcher K et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged study, BAFTA): a randomized controlled trial. Lancet 370(9586), 493-503 (2007). (Pubitemid 47212371)
99. Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet 367(9526), 1903-1912 (2006).
100. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285(22), 2864-2870 (2001). (Pubitemid 32537350)
101. Gage BF, van Walraven C, Pearce L et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 110(16), 2287-2292 (2004). (Pubitemid 39407328)
102. Sercock PA, Counsell C, Kamal AK. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst. Rev. 40(4), CD000024 (2008).
103. Lavallee PC, Meseguer E, Abboud H et al. A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility effects. Lancet Neurol. 6(11), 953-960 (2007). (Pubitemid 47570023)
104. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 105(22), 2625-2631 (2002). (Pubitemid 34596039)
105. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. NEJM 325(7), 445-453 (1991).
106. Endarterectomy for moderate symptomatic carotid stenosis: interim results from the MRC European Carotid Surgery Trial. Lancet 347(9015), 1591-1593 (1996).
107. Cina CS, Clase CM, Haynes BR. Refining the indications for carotid endarterectomy in patients with symptomatic carotid stenosis: a systematic review. J. Vasc. Surg. 30(4), 606-617 (1999).
108. Ringleb PA, Chatellier G, Hacke W et al. Safety of endovascular treatment of carotid artery stenosis compared with surgical treatment: a meta-analysis. J. Vasc. Surg. 47(2), 350-355 (2008). (Pubitemid 351172672)
109. Ringleb PA, Allenberg J, Bruckmann H et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomized non-inferiority trial. Lancet 368(9543), 1239-1247 (2006).
110. Mas JL, Trinquart L, Leys D et al. Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) Trial: results up to 4 years from a randomized, multicentre trial. Lancet Neurol. 7(10), 885-892 (2008).
111. Mas JL, Chatellier G, Beyssen B et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. NEJM 355(16), 1660-1671 (2006). (Pubitemid 44583956)
112. Stingele R, Berger J, Alfke K et al. Clinical angiographic risk factors for stroke death within 30 days after carotid endarterectomy stent-protected angioplasty: a subanalysis of the SPACE study. Lancet Neurol. 7(3), 216-222 (2008).
113. Fiehler J, Jansen O, Berger J, Eckstein HH, Ringleb PA, Stingele R. Differences in complication rates among the centres in the SPACE study. Neuroradiology 50(12), 1049-1053 (2008).
114. Stettler C, Allemann S, Juni P et al. Glycemic control macrovascular disease in Types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J, 152(1), 27-38 (2006). (Pubitemid 43974725)
115. Wilcox R, Bousser MG, Betteridge DJ et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective PioglitAzone Clinical Trial in MacroVascular Events 04). Stroke 38(3), 865-873 (2007). (Pubitemid 46568445)
116. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control vascular outcomes in patients with Type 2 diabetes. NEJM 358(24), 2560-2572 (2008). (Pubitemid 351831357)
117. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. NEJM 358(24), 2545-2559 (2008).
118. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomized trials. Lancet 361(9374), 2017-2023 (2003). (Pubitemid 36695043)
119. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary secondary prevention: systematic review meta-analysis. JAMA 297(8), 842-857 (2007). (Pubitemid 46333949)
120. Toole JF, Malinow MR, Chambless LE et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent Stroke myocardial infarction, death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291(5), 565-575 (2004).
121. Lonn E, Yusuf S, Arnold MJ et al. Homocysteine lowering with folic acid B vitamins in vascular disease. NEJM 354(15), 1567-1577 (2006).
122. Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E. Homocysteine-lowering therapy stroke risk, severity, disability. Additional findings from the HOPE 2 Trial. Stroke (2009).
123. The VITATOPS (Vitamins to Prevent Stroke) Trial: rationale design of an international, large, simple, randomized trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis, 13(2), 120-126 (2002).
124. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ 298(6676), 789-794 (1989). (Pubitemid 19084523)
125. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension, 42(5), 878-884 (2003).
126. Deplanque D, Masse I, Lefebvre C, Libersa C, Leys D, Bordet R. Prior TIA, lipid-lowering drug use, physical activity decrease ischemic stroke severity. Neurology 67(8), 1403-1410 (2006). (Pubitemid 44632064)
127. Bassetti CL, Milanova M, Gugger M. Sleep-disordered breathing acute ischemic stroke: diagnosis, risk factors, treatment, evolution, long-term clinical outcome. Stroke 37(4), 967-972 (2006).
128. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. NEJM 345(17), 1243-1249 (2001). (Pubitemid 34951488)
129. Sundell L, Salomaa V, Vartiainen E, Poikolainen K, Laatikainen T. Increased stroke risk is related to a binge drinking habit. Stroke (2008).
130. Arzt M, Young T, Finn L, Skatrud JB, Bradley TD. Association of sleep-disordered breathing the occurrence of stroke. Am. J. Respir. Crit. Care Med. 172(11), 1447-1451 (2005). (Pubitemid 43069819)
131. Mas JL, Arquizan C, Lamy C et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. NEJM 345(24), 1740-1746 (2001). (Pubitemid 34940229)
132. Windecker S, Meier B. Is closure recommended for patent foramen ovale cryptogenic stroke? Patent foramen ovale cryptogenic stroke: to close or not to close? Closure: what else! Circulation, 118(19), 1989-1998 (2008).
133. Wahl A, Krumsdorf U, Meier B et al. Transcatheter treatment of atrial septal aneurysm associated with patent foramen ovale for prevention of recurrent paradoxical embolism in high-risk patients. J. Am. Coll. Cardiol. 45(3), 377-380 (2005). (Pubitemid 40186787)
134. Windecker S, Wahl A, Nedeltchev K et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J. Am. Coll. Cardiol. 44(4), 750-758 (2004). (Pubitemid 39099567)
135. Khairy P, O'Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale presumed paradoxical thromboemboli: a systematic review. Ann Intern Med, 139(9), 753-760 (2003). (Pubitemid 38129075)
136. Yamamoto H, Bogousslavsky J. Mechanisms of second further strokes. J. Neurol. Neurosurg. Psychiatr. 64(6), 771-776 (1998).
137. Rothwell PM, Giles MF, Chandratheva A et al. Effect of urgent treatment of transient ischaemic attack minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 370(9596), 1432-1442 (2007). (Pubitemid 47576154)
138. Johnston SC, Rothwell PM, Nguyen-Huynh MN et al. Validation refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 369(9558), 283-292 (2007).